Nosocomial Staphylococcus aureus infection.
Conditions
Interventions
The comparison intervention consists of mupirocin 2% nasal ointment and chlorhexidindigluconate 4% body soap. The control intervention consists of placebo nasal ointment and placebo body soap. Patient
Sponsors
Primary sponsor:
Department of Medical Microbiology and Infectious Disease at Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Secondary sponsors:
Canisius Wilhelmina hospital, Nijmegen, the Netherlands
Amphia hospital, Breda, the Netherlands
University Medical Center Utrecht, Utrecht, the Netherlands
VU Medical Center, Amsterdam, the Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult patients (>= 18 years); 2. Rapid detection positive for S. aureus nasal carriage; 3. Expected admission of >= 4 days; 4. Treatment can be started <= 24 hours after admission; 5. Informed consent.
Exclusion criteria
Exclusion criteria: 1. S. aureus infection at enrollment; 2. Allergy to mupirocin; 3. Allergy to chlorhexidin; 4. Pregnancy or lactation; 5. Recent (< 4 weeks) mupirocin use; 6. Nasal corpus alienum.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nosocomial S. aureus infection until 6 weeks after discharge according to CDC-criteria. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Duration of hospital stay; 2. In-hospital mortality; 3. Time to nosocomial S. aureus infection. | — |
Contacts
Public ContactLonneke Bode
Erasmus Medical Center, Department of Medical Microbiology and Infectious Diseases, Dr. Molewaterplein 40
Outcome results
None listed